Aberdeen Group’s iShares Biotechnology ETF IBB Stock Holding History

Aberdeen Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-43,634	Closed	-$5.99M	–	961
2024 Q1	$5.99M	Hold	43,634	–	–	0.01%	641
2023 Q4	$5.93M	Buy	+43,634	New	+$5.32M	0.01%	642

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Aberdeen Group's IBB Position: Q2 2024 in Review

Aberdeen Group sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 43,634 shares — an estimated $5.99M sold.

Aberdeen Group first reported a position in IBB in Q4 2023 and held it in 2 quarters. The position peaked at $5.99M in Q1 2024. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

Aberdeen Group reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
Aberdeen Group sold 43,634 iShares Biotechnology ETF shares in Q2 2024, an estimated $5.99M.
Aberdeen Group first reported a position in iShares Biotechnology ETF in Q4 2023 and held it in 2 quarters.
Aberdeen Group's iShares Biotechnology ETF position peaked at $5.99M in Q1 2024.
894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Aberdeen Group's 13F filing for Q2 2024, filed 9 Aug 2024.